AJMC November 11, 2021
Tony Hagen

There is now a mad scramble to gain interchangeable status for biosimilars, but the meaning and significance of this appellation haven’t yet been worked out for health care consumers or the manufacturing community.

In July 2021, the FDA approved an insulin glargine drug as not only a biosimilar but also the first “interchangeable,” meaning pharmacists could use their own discretion in dispensing this product to patients without having to seek provider authorization. It was then that things started to happen for this drug (Semglee), which had previously been available as an equivalent to Lantus, the reference product, but was not considered a biosimilar.

The biosimilar status, which was applied for by Biocon Biologics and Mylan, represented FDA certification that the...

Today's Sponsors

Patient Bond
Institute for Healthcare Improvement

Today's Sponsors

Oliver Wyman
Patient Bond

Today's Sponsor

Patient Bond

Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Panelists Explore What Exactly Is Holding Up US Adoption of Biosimilars
A biotech wins the first FDA drug approval in a rare type of eye cancer
CRISPR: Maximizing this Revolutionary Genetic Tool While Minimizing IP Risk
Concerns Mount Over Limited Evidence for Accelerated Approvals
70% of healthcare execs expect M&A activity to rise this year